In addition, our results showed that XKY treatment significantly diminished hepatic lipid deposition and steatosis accompanied by improved liver function (ATL and AST), lipid profile (TC and TG) and inflammation (TNF-α and IL-6) in db/db mice. The gene discussed is IL6; the disease is steatosis.